Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/5169
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | APRAHAMIAN, Ivan | - |
dc.contributor.author | STELLA, Florindo | - |
dc.contributor.author | FORLENZA, Orestes V. | - |
dc.date.accessioned | 2014-04-25T21:54:18Z | - |
dc.date.available | 2014-04-25T21:54:18Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | INDIAN JOURNAL OF MEDICAL RESEARCH, v.138, p.449-460, 2013 | - |
dc.identifier.issn | 0971-5916 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/5169 | - |
dc.description.abstract | Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease, and corresponds to the most common cause of dementia worldwide. Although not fully understood, the pathophysiology of AD is largely represented by the neurotoxic events triggered by the beta-amyloid cascade and by cytoskeletal abnormalities subsequent to the hyperphosphorylation of microtubule-associated Tau protein in neurons. These processes lead respectively to the formation of neuritic plaques and neurofibrillary tangles, which are the pathological hallmarks of the disease. Clinical benefits of the available pharmacological treatment for AD with antidementia drugs (namely cholinesterase inhibitors and memantine) are unquestionable, although limited to a temporary, symptomatic support to cognitive and related functions. Over the past decade, substantial funding and research have been dedicated to the search and development of new pharmaceutical compounds with disease-modifying properties. The rationale of such approach is that by tackling key pathological processes in AD it may be possible to attenuate or even change its natural history. In the present review, we summarize the available evidence on the new therapeutic approaches that target amyloid and Tau pathology in AD, focusing on pharmaceutical compounds undergoing phase 2 and phase 3 randomized controlled trials. | - |
dc.language.iso | eng | - |
dc.publisher | INDIAN COUNCIL MEDICAL RES | - |
dc.relation.ispartof | Indian Journal of Medical Research | - |
dc.rights | openAccess | - |
dc.subject | Alzheimer's disease | - |
dc.subject | antidementia drug | - |
dc.subject | beta-amyloid | - |
dc.subject | cognitive impairment | - |
dc.subject | Tau | - |
dc.subject | treatment | - |
dc.subject.other | mild cognitive impairment | - |
dc.subject.other | glycogen-synthase kinase-3-beta | - |
dc.subject.other | chronic divalproex sodium | - |
dc.subject.other | amyloid-beta peptide | - |
dc.subject.other | app transgenic mice | - |
dc.subject.other | a-beta | - |
dc.subject.other | imaging abnormalities | - |
dc.subject.other | selective-inhibition | - |
dc.subject.other | vascular dementia | - |
dc.subject.other | modifying trials | - |
dc.title | New treatment strategies for Alzheimer's disease: is there a hope? | - |
dc.type | article | - |
dc.rights.holder | Copyright INDIAN COUNCIL MEDICAL RES | - |
dc.identifier.pmid | 24434253 | - |
dc.subject.wos | Immunology | - |
dc.subject.wos | Medicine, General & Internal | - |
dc.subject.wos | Medicine, Research & Experimental | - |
dc.type.category | review | - |
dc.type.version | publishedVersion | - |
hcfmusp.description.beginpage | 449 | - |
hcfmusp.description.endpage | 460 | - |
hcfmusp.description.volume | 138 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | 2-s2.0-84887384043 | - |
hcfmusp.origem.id | WOS:000330872300004 | - |
hcfmusp.publisher.city | NEW DELHI | - |
hcfmusp.publisher.country | INDIA | - |
hcfmusp.relation.reference | Albright CF, 2013, J PHARMACOL EXP THER, V344, P686, DOI 10.1124/jpet.112.199356 | - |
hcfmusp.relation.reference | [Anonymous], 2012, EUR FED NEUR SOC ANN | - |
hcfmusp.relation.reference | Ballard C, 2011, LANCET, V377, P1019, DOI 10.1016/S0140-6736(10)61349-9 | - |
hcfmusp.relation.reference | Barakos J, 2011, ALZHEIMERS DEMENTI S, V7, pe75 | - |
hcfmusp.relation.reference | Bard F, 2012, EXP NEUROL, V238, P38, DOI 10.1016/j.expneurol.2012.07.022 | - |
hcfmusp.relation.reference | Bolognesi ML, 2011, BIOORG MED CHEM LETT, V21, P2655, DOI 10.1016/j.bmcl.2010.12.093 | - |
hcfmusp.relation.reference | Bourgeat P, 2010, NEUROLOGY, V74, P121, DOI 10.1212/WNL.0b013e3181c918b5 | - |
hcfmusp.relation.reference | Burstein AH, 2013, CLIN NEUROPHARMACOL, V36, P8, DOI 10.1097/WNF.0b013e318279bcfa | - |
hcfmusp.relation.reference | Caccamo A, 2007, AM J PATHOL, V170, P1669, DOI 10.2353/ajpath.2007.061178 | - |
hcfmusp.relation.reference | Caraci F, 2011, CNS NEUROSCI THER, V17, P237, DOI 10.1111/j.1755-5949.2009.00115.x | - |
hcfmusp.relation.reference | Carlson C, 2011, ALZHEIMERS DEMENT, V7, P396, DOI 10.1016/j.jalz.2011.05.2353 | - |
hcfmusp.relation.reference | Chandra V, 1998, NEUROLOGY, V51, P1000 | - |
hcfmusp.relation.reference | Chang WP, 2011, FASEB J, V25, P775, DOI 10.1096/fj.10-167213 | - |
hcfmusp.relation.reference | Coric V, 2012, ARCH NEUROL-CHICAGO, V69, P1430, DOI 10.1001/archneurol.2012.2194 | - |
hcfmusp.relation.reference | Cummings Jeffrey L, 2011, Alzheimers Dement, V7, pe13, DOI 10.1016/j.jalz.2010.06.004 | - |
hcfmusp.relation.reference | Das SK, 2007, NEUROLOGY, V68, P2019, DOI 10.1212/01.wnl.0000264424.76759.e6 | - |
hcfmusp.relation.reference | Davtyan H, 2013, J NEUROSCI, V33, P4923, DOI 10.1523/JNEUROSCI.4672-12.2013 | - |
hcfmusp.relation.reference | DUBOIS B, 2010, LANCET NEUROL, V9, P1118, DOI 10.1016/S1474-4422(10)70223-4 | - |
hcfmusp.relation.reference | Fleisher AS, 2011, NEUROLOGY, V77, P1263, DOI 10.1212/WNL.0b013e318230a16c | - |
hcfmusp.relation.reference | Forlenza OV, 2011, BRIT J PSYCHIAT, V198, P351, DOI 10.1192/bjp.bp.110.080044 | - |
hcfmusp.relation.reference | Forlenza OV, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-89 | - |
hcfmusp.relation.reference | Ganguli M, 2000, ARCH NEUROL-CHICAGO, V57, P824, DOI 10.1001/archneur.57.6.824 | - |
hcfmusp.relation.reference | Hamada Y, 2013, EXPERT OPIN DRUG DIS, V8, P709, DOI 10.1517/17460441.2013.784267 | - |
hcfmusp.relation.reference | Hampel H, 2012, INT PSYCHOGERIATR, V24, pS10, DOI 10.1017/S1041610212000579 | - |
hcfmusp.relation.reference | Hampel H, 2009, J CLIN PSYCHIAT, V70, P922 | - |
hcfmusp.relation.reference | Hanger DP, 2009, TRENDS MOL MED, V15, P112, DOI 10.1016/j.molmed.2009.01.003 | - |
hcfmusp.relation.reference | Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994 | - |
hcfmusp.relation.reference | Hardy J, 2009, J NEUROCHEM, V110, P1129, DOI 10.1111/j.1471-4159.2009.06181.x | - |
hcfmusp.relation.reference | Hardy John, 2006, Current Alzheimer Research, V3, P71, DOI 10.2174/156720506775697098 | - |
hcfmusp.relation.reference | Hooper C, 2008, J NEUROCHEM, V104, P1433, DOI 10.1111/j.1471-4159.2007.05194.x | - |
hcfmusp.relation.reference | Hsu CK, 2013, J AM ACAD DERMATOL, V68, pE46, DOI 10.1016/j.jaad.2012.07.012 | - |
hcfmusp.relation.reference | Jack CR, 2013, LANCET NEUROL, V12, P207, DOI 10.1016/S1474-4422(12)70291-0 | - |
hcfmusp.relation.reference | Jack CR, 2009, BRAIN, V132, P1355, DOI 10.1093/brain/awp062 | - |
hcfmusp.relation.reference | Kalaria RN, 2008, LANCET NEUROL, V7, P812, DOI 10.1016/S1474-4422(08)70169-8 | - |
hcfmusp.relation.reference | Landen JW, 2013, CLIN NEUROPHARMACOL, V36, P14, DOI 10.1097/WNF.0b013e31827db49b | - |
hcfmusp.relation.reference | Lauterbach EC, 2010, J NEUROPSYCH CLIN N, V22, P8, DOI 10.1176/appi.neuropsych.22.1.8 | - |
hcfmusp.relation.reference | Macdonald A, 2008, INT J GERIATR PSYCH, V23, P704, DOI 10.1002/gps.1964 | - |
hcfmusp.relation.reference | Mangialasche F, 2010, LANCET NEUROL, V9, P702, DOI 10.1016/S1474-4422(10)70119-8 | - |
hcfmusp.relation.reference | Martin L, 2009, BRAIN RES, V1252, P66, DOI 10.1016/j.brainres.2008.11.057 | - |
hcfmusp.relation.reference | Mathew A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032616 | - |
hcfmusp.relation.reference | Mathuranath PS, 2010, INT J GERIATR PSYCH, V25, P290, DOI 10.1002/gps.2338 | - |
hcfmusp.relation.reference | McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M | - |
hcfmusp.relation.reference | Medina DX, 2011, BRAIN PATHOL, V21, P140, DOI 10.1111/j.1750-3639.2010.00430.x | - |
hcfmusp.relation.reference | Meraz-Rios MA, 2010, J NEUROCHEM, V112, P1353, DOI 10.1111/j.1471-4159.2009.06511.x | - |
hcfmusp.relation.reference | Mhyre TR, 2008, NEUROBIOL AGING, V29, P1631, DOI 10.1016/j.neurobiolaging.2007.04.004 | - |
hcfmusp.relation.reference | Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116 | - |
hcfmusp.relation.reference | Morris R, 2006, NATURE, V440, P284, DOI 10.1038/440284a | - |
hcfmusp.relation.reference | Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840 | - |
hcfmusp.relation.reference | Nordberg A, 2011, ALZHEIMERS RES THER, V3, P1 | - |
hcfmusp.relation.reference | Nunes PV, 2007, BRIT J PSYCHIAT, V190, P359, DOI 10.1192/bjp.bp.106.029868 | - |
hcfmusp.relation.reference | Oz M, 2009, BIOCHEM PHARMACOL, V78, P927, DOI 10.1016/j.bcp.2009.04.034 | - |
hcfmusp.relation.reference | Ozudogru SN, 2012, AM J ALZHEIMERS DIS, V27, P296, DOI 10.1177/1533317512452034 | - |
hcfmusp.relation.reference | Panza F, 2011, CURR ALZHEIMER RES, V8, P808 | - |
hcfmusp.relation.reference | Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011 | - |
hcfmusp.relation.reference | Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640 | - |
hcfmusp.relation.reference | Piazza F, 2013, ANN NEUROL, V73, P449, DOI 10.1002/ana.23857 | - |
hcfmusp.relation.reference | Pinto C, 2006, INT PSYCHOGERIATR, V18, P87, DOI 10.1017/S104161020500311X | - |
hcfmusp.relation.reference | Purohit DP, 2011, J ALZHEIMERS DIS, V24, P187, DOI 10.3233/JAD-2010-101698 | - |
hcfmusp.relation.reference | Salloway S, 2009, NEUROLOGY, V73, P2061, DOI 10.1212/WNL.0b013e3181c67808 | - |
hcfmusp.relation.reference | Salomone S, 2012, BRIT J CLIN PHARMACO, V73, P504, DOI 10.1111/j.1365-2125.2011.04134.x | - |
hcfmusp.relation.reference | Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124 | - |
hcfmusp.relation.reference | Sereno L, 2009, NEUROBIOL DIS, V35, P359, DOI 10.1016/j.nbd.2009.05.025 | - |
hcfmusp.relation.reference | Sivilia S, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-44 | - |
hcfmusp.relation.reference | Solomon B, 2009, THESCIENTIFICWORLDJO, V9, P909, DOI 10.1100/tsw.2009.99 | - |
hcfmusp.relation.reference | Sperling R, 2012, LANCET NEUROL, V11, P241, DOI 10.1016/S1474-4422(12)70015-7 | - |
hcfmusp.relation.reference | Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P367, DOI 10.1016/j.jalz.2011.05.2351 | - |
hcfmusp.relation.reference | Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003 | - |
hcfmusp.relation.reference | Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681 | - |
hcfmusp.relation.reference | Takashima A, 1998, NEUROSCI RES, V31, P317, DOI 10.1016/S0168-0102(98)00061-3 | - |
hcfmusp.relation.reference | Takashima A, 2009, J ALZHEIMERS DIS, V17, P729, DOI 10.3233/JAD-2009-1090 | - |
hcfmusp.relation.reference | Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008 | - |
hcfmusp.relation.reference | Tariot PN, 2011, ARCH GEN PSYCHIAT, V68, P853, DOI 10.1001/archgenpsychiatry.2011.72 | - |
hcfmusp.relation.reference | Tariot PN, 2009, J CLIN PSYCHIAT, V70, P919 | - |
hcfmusp.relation.reference | Tripathi M, 2012, AGING MENT HEALTH, V16, P228, DOI 10.1080/13607863.2011.583632 | - |
hcfmusp.relation.reference | Uenaka K, 2012, CLIN NEUROPHARMACOL, V35, P25, DOI 10.1097/WNF.0b013e31823a13d3 | - |
hcfmusp.relation.reference | Vellas B, 2007, LANCET NEUROL, V6, P56, DOI 10.1016/S1474-4422(06)70677-9 | - |
hcfmusp.relation.reference | Wada A, 2005, J PHARMACOL SCI, V99, P307, DOI 10.1254/jphs.CRJ05009X | - |
hcfmusp.relation.reference | Werring DJ, 2013, ANN NEUROL, V73, P439, DOI 10.1002/ana.23891 | - |
hcfmusp.relation.reference | Wiessner C, 2011, J NEUROSCI, V31, P9323, DOI 10.1523/JNEUROSCI.0293-11.2011 | - |
hcfmusp.relation.reference | Wischik C, 2009, J NUTR HEALTH AGING, V13, P367, DOI 10.1007/s12603-009-0046-5 | - |
hcfmusp.relation.reference | Wischik CM, 1996, P NATL ACAD SCI USA, V93, P11213, DOI 10.1073/pnas.93.20.11213 | - |
hcfmusp.relation.reference | World Health Organization (WHO), 2002, WHONMHNPH028 | - |
hcfmusp.relation.reference | Yeh HL, 2007, MED HYPOTHESES, V71, P948 | - |
dc.description.index | MEDLINE | - |
hcfmusp.citation.scopus | 51 | - |
hcfmusp.scopus.lastupdate | 2024-03-29 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MPS Artigos e Materiais de Revistas Científicas - HC/IPq Artigos e Materiais de Revistas Científicas - LIM/27 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_APRAHAMIAN_New_treatment_strategies_for_Alzheimer_s_disease_is_2013.PDF | publishedVersion (English) | 1.2 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.